Chronic refractory cough

Merck; Bayer; Shionogi set to showcase their candidates indicated for Chronic RefractoryCough in the ATS Virtual Conference

  • by

Merck’s Gefapixant could become the first drug approved for Chronic Cough ATS 2020 Virtual is happening from August 5 to August 10, and it is exciting to watch major Respiratory /Pulmonary Pharmaceutical companies and their key presentations. Merck is worth mentioning here, as it is… Read More »Merck; Bayer; Shionogi set to showcase their candidates indicated for Chronic RefractoryCough in the ATS Virtual Conference